A University of Basel spin-off, Aukera Therapeutics develops selective mTORC1 (RAPTOR) inhibitors, initially for tuberous sclerosis complex. Former Numab CEO David Urech has invested an undisclosed amount; the company has raised CHF 4.5 million in total, notably from Kickfund and Zürcher Kantonalbank.
- Announced on
- Round
- Undisclosed round
- Amount
- Amount not disclosed
- Location
- canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- David Urech
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic